Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CDKN2A loss Palbociclib chordoma sensitive detail...
CDKN2A loss Abemaciclib chordoma sensitive detail...
Unknown unknown Dasatinib chordoma not applicable detail...
SMARCB1 negative Tazemetostat chordoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01407198 Phase I Nilotinib Nilotinib With Radiation for High Risk Chordoma Active, not recruiting
NCT02383498 Phase II GI-6301 The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma Active, not recruiting
NCT02989636 Phase I Nivolumab Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Recruiting
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting
NCT03623854 Phase II Nivolumab + Relatlimab Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma Recruiting
NCT03647423 Phase Ib/II Aldoxorubicin + ALT-803 + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Withdrawn
NCT03886311 Phase II Nivolumab + Talimogene laherparepvec + Trabectedin Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) Recruiting